Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Enhanced detection of circulating tumor DNA by fragment size analysis.

Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T, Marass F, Heider K, Wan JCM, Supernat A, Hudecova I, Gounaris I, Ros S, Jimenez-Linan M, Garcia-Corbacho J, Patel K, Østrup O, Murphy S, Eldridge MD, Gale D, Stewart GD, Burge J, Cooper WN, van der Heijden MS, Massie CE, Watts C, Corrie P, Pacey S, Brindle KM, Baird RD, Mau-Sørensen M, Parkinson CA, Smith CG, Brenton JD, Rosenfeld N.

Sci Transl Med. 2018 Nov 7;10(466). pii: eaat4921. doi: 10.1126/scitranslmed.aat4921.

PMID:
30404863
2.

A novel Atg5-shRNA mouse model enables temporal control of Autophagy in vivo.

Cassidy LD, Young AR, Pérez-Mancera PA, Nimmervoll B, Jaulim A, Chen HC, McIntyre DJO, Brais R, Ricketts T, Pacey S, De La Roche M, Gilbertson RJ, Rubinsztein DC, Narita M.

Autophagy. 2018;14(7):1256-1266. doi: 10.1080/15548627.2018.1458172. Epub 2018 Jul 12.

3.

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.

Beddowes E, Spicer J, Chan PY, Khadeir R, Corbacho JG, Repana D, Steele JP, Schmid P, Szyszko T, Cook G, Diaz M, Feng X, Johnston A, Thomson J, Sheaff M, Wu BW, Bomalaski J, Pacey S, Szlosarek PW.

J Clin Oncol. 2017 Jun 1;35(16):1778-1785. doi: 10.1200/JCO.2016.71.3230. Epub 2017 Apr 7.

4.

The role of chemotherapy and new targeted agents in the management of primary prostate cancer.

Kumar SS, Pacey S.

J Clin Urol. 2016 Dec;9(2 Suppl):30-37. doi: 10.1177/2051415816685211. Epub 2016 Dec 1.

5.

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N.

Nat Rev Cancer. 2017 Apr;17(4):223-238. doi: 10.1038/nrc.2017.7. Epub 2017 Feb 24. Review.

PMID:
28233803
6.

Patient and public understanding and knowledge of antimicrobial resistance and stewardship in a UK hospital: should public campaigns change focus?

Micallef C, Kildonaviciute K, Castro-Sánchez E, Scibor-Stepien A, Santos R, Aliyu SH, Cooke FJ, Pacey S, Holmes AH, Enoch DA.

J Antimicrob Chemother. 2017 Jan;72(1):311-314. Epub 2016 Sep 21.

7.

Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma.

Al-Lamki RS, Wang J, Yang J, Burrows N, Maxwell PH, Eisen T, Warren AY, Vanharanta S, Pacey S, Vandenabeele P, Pober JS, Bradley JR.

Oncotarget. 2016 Apr 26;7(17):24111-24. doi: 10.18632/oncotarget.8125.

8.

Glutamine supplementation in cystic fibrosis: A randomized placebo-controlled trial.

Forrester DL, Knox AJ, Smyth AR, Barr HL, Simms R, Pacey SJ, Pavord ID, Honeybourne D, Dewar J, Clayton A, Fogarty AW.

Pediatr Pulmonol. 2016 Mar;51(3):253-7. doi: 10.1002/ppul.23370. Epub 2015 Dec 27.

PMID:
26709241
9.

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.

Tan CS, Gilligan D, Pacey S.

Lancet Oncol. 2015 Sep;16(9):e447-e459. doi: 10.1016/S1470-2045(15)00246-6. Review.

PMID:
26370354
10.

Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.

Lee CP, Taylor NJ, Attard G, Pacey S, Nathan PD, de Bono JS, Temple G, Bell S, Stefanic M, Stopfer P, Tang A, Koh DM, Collins DJ, d'Arcy J, Padhani AR, Leach MO, Judson IR, Rustin GJ.

Oncologist. 2015 Apr;20(4):368-9. doi: 10.1634/theoncologist.2014-0250. Epub 2015 Mar 20.

11.

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.

Zimmer L, Barlesi F, Martinez-Garcia M, Dieras V, Schellens JH, Spano JP, Middleton MR, Calvo E, Paz-Ares L, Larkin J, Pacey S, Venturi M, Kraeber-Bodéré F, Tessier JJ, Eberhardt WE, Paques M, Guarin E, Meresse V, Soria JC.

Clin Cancer Res. 2014 Aug 15;20(16):4251-61. doi: 10.1158/1078-0432.CCR-14-0341. Epub 2014 Jun 19.

12.

A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.

Powles T, Foreshew SJ, Shamash J, Sarwar N, Crabb S, Sahdev A, Nixon J, Lim L, Pungaliya A, Foreshaw A, Davies R, Greenwood M, Wilson P, Pacey S, Galazi M, Jones R, Chowdhury S.

Eur J Cancer. 2014 Aug;50(12):2057-64. doi: 10.1016/j.ejca.2014.04.021. Epub 2014 Jun 4.

PMID:
24908540
13.

A 46 year old man with carcinoma of unknown primary site.

Liniker E, Al-Jilaihawi S, Propper D, Slater S, Pacey S.

BMJ. 2012 Aug 2;345:e5144. doi: 10.1136/bmj.e5144. No abstract available.

PMID:
22859798
14.

Another patient with low back pain.

O'Leary B, Eminowicz G, Powell ME, Pacey S.

BMJ. 2012 Jun 14;344:e3510. doi: 10.1136/bmj.e3510. No abstract available.

PMID:
22700783
15.

A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.

Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, Workman P, Judson I.

Clin Cancer Res. 2011 Mar 15;17(6):1561-70. doi: 10.1158/1078-0432.CCR-10-1927. Epub 2011 Jan 28. Erratum in: Clin Cancer Res. 2018 Nov 1;24(21):5488.

16.

A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.

Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S, Owen K, Asad Y, Raynaud F, Walton M, Judson I, Workman P, Eisen T.

Invest New Drugs. 2012 Feb;30(1):341-9. doi: 10.1007/s10637-010-9493-4. Epub 2010 Aug 5.

PMID:
20683637
17.

Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.

Vaishampayan UN, Burger AM, Sausville EA, Heilbrun LK, Li J, Horiba MN, Egorin MJ, Ivy P, Pacey S, Lorusso PM.

Clin Cancer Res. 2010 Jul 15;16(14):3795-804. doi: 10.1158/1078-0432.CCR-10-0503. Epub 2010 Jun 4.

18.

Impact of adopting low sodium diet on biomarkers of inflammation and coagulation: a randomised controlled trial.

Forrester DL, Britton J, Lewis SA, Pogson Z, Antoniak M, Pacey SJ, Purcell G, Fogarty AW.

J Nephrol. 2010 Jan-Feb;23(1):49-54.

PMID:
20091486
19.

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.

Pacey S, Ratain MJ, Flaherty KT, Kaye SB, Cupit L, Rowinsky EK, Xia C, O'Dwyer PJ, Judson IR.

Invest New Drugs. 2011 Jun;29(3):481-8. doi: 10.1007/s10637-009-9367-9. Epub 2009 Dec 18.

PMID:
20016927
20.

Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.

Gaspar N, Sharp SY, Pacey S, Jones C, Walton M, Vassal G, Eccles S, Pearson A, Workman P.

Cancer Res. 2009 Mar 1;69(5):1966-75. doi: 10.1158/0008-5472.CAN-08-3131. Epub 2009 Feb 24. Erratum in: Cancer Res. 2009 Apr 15;69(8):3721.

21.

Does a low sodium diet modify heart rate variability? A randomised placebo-controlled double-blind trial.

Pogson ZE, McKeever TM, Lewis SA, Pacey SJ, Antoniak MD, Britton JR, Fogarty AW.

Int J Cardiol. 2009 Jul 10;135(3):390-3. doi: 10.1016/j.ijcard.2008.11.004. Epub 2008 Dec 4.

PMID:
19062112
22.

Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.

de Bono JS, Kristeleit R, Tolcher A, Fong P, Pacey S, Karavasilis V, Mita M, Shaw H, Workman P, Kaye S, Rowinsky EK, Aherne W, Atadja P, Scott JW, Patnaik A.

Clin Cancer Res. 2008 Oct 15;14(20):6663-73. doi: 10.1158/1078-0432.CCR-08-0376.

23.

Does a low sodium diet improve asthma control? A randomized controlled trial.

Pogson ZE, Antoniak MD, Pacey SJ, Lewis SA, Britton JR, Fogarty AW.

Am J Respir Crit Care Med. 2008 Jul 15;178(2):132-8. doi: 10.1164/rccm.200802-287OC. Epub 2008 May 1.

PMID:
18451321
24.

Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.

Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, Barrett M, Judson I, Kaye S, Fox NL, Halpern W, Corey A, Calvert H, de Bono J.

Clin Cancer Res. 2007 Oct 15;13(20):6187-94.

25.

Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development.

Sarker D, Pacey S, Workman P.

Biomark Med. 2007 Oct;1(3):399-417. doi: 10.2217/17520363.1.3.399.

PMID:
20477383
26.

Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of the novel anticancer agent 17-DMAG in human plasma.

Moreno-Farre J, Asad Y, Pacey S, Workman P, Raynaud FI.

Rapid Commun Mass Spectrom. 2006;20(19):2845-50.

PMID:
16941534
27.

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours.

Greystoke A, Blagden S, Thomas AL, Scott E, Attard G, Molife R, Vidal L, Pacey S, Sarkar D, Jenner A, De-Bono JS, Steward W.

Ann Oncol. 2006 Aug;17(8):1313-9. Epub 2006 May 25.

PMID:
16728482
28.

Hsp90 inhibitors in the clinic.

Pacey S, Banerji U, Judson I, Workman P.

Handb Exp Pharmacol. 2006;(172):331-58. Review.

PMID:
16610366
29.

Low dose erythropoietin is effective in reducing transfusion requirements following allogeneic HSCT.

Fox CP, Pacey S, Das-Gupta EP, Russell NH, Byrne JL.

Transfus Med. 2005 Dec;15(6):475-80.

PMID:
16359418
30.

Corticosteroid sparing effects of vitamin C and magnesium in asthma: a randomised trial.

Fogarty A, Lewis SA, Scrivener SL, Antoniak M, Pacey S, Pringle M, Britton J.

Respir Med. 2006 Jan;100(1):174-9. Epub 2005 Apr 26.

31.

Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.

Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P, Judson I.

J Clin Oncol. 2005 Jun 20;23(18):4152-61.

PMID:
15961763
32.

Oral magnesium and vitamin C supplements in asthma: a parallel group randomized placebo-controlled trial.

Fogarty A, Lewis SA, Scrivener SL, Antoniak M, Pacey S, Pringle M, Britton J.

Clin Exp Allergy. 2003 Oct;33(10):1355-9.

PMID:
14519140
33.

A multidisciplinary approach to hospital-based drug cost containment.

Pacey S, Warner J, Li Wan Po A.

J Clin Pharm Ther. 1998 Jun;23(3):203-11.

PMID:
9831972
34.

A review of methods of drug cost management in hospitals.

Pacey S, Li Wan Po A.

J Clin Pharm Ther. 1998 Jun;23(3):171-7. Review.

PMID:
9831967
35.

Inhibition of neuronal high voltage-activated calcium channels by insect peptides: a comparison with the actions of omega-conotoxin GVIA.

Scott RH, Gorton VJ, Harding L, Patel D, Pacey S, Kellenberger C, Hietter H, Bermudez I.

Neuropharmacology. 1997 Feb;36(2):195-208.

PMID:
9144657
37.

Economic evaluation of peripheral blood stem cell transplantation for lymphoma.

Russell NH, Pacey S.

Lancet. 1992 Nov 21;340(8830):1290. No abstract available.

PMID:
1359344
38.

Letter: Beta-blocking drugs.

Pacey SM.

Med J Aust. 1973 Sep 8;2(10):521. No abstract available.

PMID:
4147999

Supplemental Content

Support Center